SG/CALL/BRISTOL-MYERS SQUIBB/55/0.1/17.01.25 | Delayed Deutsche Boerse AG 15:45:19 26/06/2024 BST | ||
| 0.047 EUR | +9.30% |
|
| Current month | +26.47% | ||
| 1 month | +10.26% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 0.047 | +9.30% |
| 25/06/24 | 0.043 | -2.27% |
| 24/06/24 | 0.044 | -2.22% |
| 21/06/24 | 0.045 | +21.62% |
| 20/06/24 | 0.037 | +19.35% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:45 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SV6TX1 |
| ISIN | DE000SV6TX15 |
| Date issued | 29/05/2023 |
| Strike | 55 $ |
| Maturity | 17/01/2025 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 1.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.45 € |
|---|---|
| Lowest since issue | 0.029 € |
| Spread | 0.01 € |
| Spread % | 17.86% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.19
USD
Average target price
53.19
USD
Spread / Average Target
+26.08%
- Stock Market
- Warrants
- Warrant
